## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Mark R. Vandlik et al.	ļ
Serial No.: 10/765,498 )	
Filed: 01/26/2004	
Examiner: Unassigned )	ı
Art Unit: 3762 )	
For: Blood Processing Systems and Methods ) That Employ An In-Line, Flexible Leukofilter)	

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Dear Sir:


Pursuant to 37 C.F.R. § 1.97, the Examiner's attention is directed to the documents listed on the attached forms, which documents may be material to the examination of this application.

No inference should be drawn that any disclosure is equivalent to the subject invention. Also, the citation of the above-discussed documents is not to be construed as an assertion that more pertinent art could not possibly be in existence.

A copy of any foreign reference(s) that was not previously submitted in a prior application which is being relied upon for an earlier filing date under 35 USC 120 (37 CFR § 1.98(d)) is submitted herewith. Applicants note that a machine translation of the Japanese reference is also being submitted.

Citation of any document herein is not to be construed as an admission that any subject matter disclosed in the document is necessarily within the inventive field of endeavor, that any disclosure is necessarily prior in time to a particular date which may be relevant to the instant patent application, and/or that any disclosure is otherwise necessarily prior art with respect to the instant invention.

The right is also reserved to later set forth how the instant invention is distinguished over the disclosure of any document or other art, including the disclosure of those documents discussed herein, that may be cited by the Examiner in rejecting a claim in the present patent application.



	ecution in the application. [Sow, as appropriate]	elect either one of the statem	ents <u>OR</u>
inf	It is hereby stated formation disclosure statement	and certified with respect to tent:	his
for	sclosure statement was first reign patent office in a count ree months prior to the filing	information contained in the incited in any communication for erpart foreign application not of the information disclosure	rom a more than
dis pa kno rea dis 1.5	That no item of infections of the sclosure statement was cited atent office in a counterpart for owledge of the person signification as onable inquiry, no item of sclosure statement was known	ormation contained in the info I in a communication from a foreign application, and, to the ing the certification after making information contained in the intermation that in the information that information the filing of the information to the filing of the information.	foreign e ng nformation ed in §
		e set forth in 37 CFR § 1.17(ps a request and authorization Account No. 50-1039.	•
statement is above) and	s being filed after the period :	97(d) this information disclos specified in 37 CFR § 1.97(c) issue fee. It is hereby state disclosure statement:	(see
for	sclosure statement was first reign patent office in a count	formation contained in the infocited in any communication from the erpart foreign application not of the information disclosure	rom a more than
pa kno rea dis 1.5	sclosure statement was cited tent office in a counterpart for owledge of the person signing asonable inquiry, no item of sclosure statement was know	mation contained in the information a communication from a foreign application, and, to the oreign application after making the certification after making information contained in the information the information the information to the filing of the information to the filing of the information to the filing of the information.	oreign e ng nformation ed in §

Also enclosed is the fee set forth in 37 CFR § 1.17(p) or in the event no fee is enclosed, this is a request and authorization to charge the appropriate fee to Deposit Account No. 50-1039.

In summary, it is respectfully requested that this Information Disclosure

Statement be considered and made of record, and that any fee required for consideration, if not authorized above, be charged to deposit account no. 50-1039.

Respectfully submitted,

Date: <u>Mar. 9</u> 2007

Gary W. McFarron

Registration No. 27,357

COOK, ALEX, MCFARRON, MANZO,

**CUMMINGS & MEHLER, LTD.** 

200 West Adams Street - Suite 2850

Chicago, IL 60606

Phone: (312)236-8500 Fax: (312)236-8176

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Complete if Known Substitute for form 1449A/PTO 10/765.498 **Application Number** INFORMATION DISCLOSURE 01/26/2004 Filing Date STATEMENT BY APPLICANT Mark R. Vandlik First Named Inventor 3762 Art Unit Unassigned **Examiner Name** (Use as many sheets as necessary) F-5489 CIP 2 CON(0360-0166.04) 1 Attorney Docket Number 1 Sheet

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
IIIIUais	NU.	Number-Kind Code <sup>2 (If known)</sup>		Appreant of Orea Document	Figures Appear
		US-			<u> </u>
	<u> </u>	US-			
		US-			4.6.3.300
		us-			
	]	US-			
		US-			
		US-			
		US-			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
		JP 07-267871	10-17-1995	Kawasumi Lab Inc.		V
	<u> </u>					

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>5</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.